<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ichikawa M</submitter><funding>Takeda Science Foundation</funding><funding>Japan Agency for Medical Research and Development</funding><funding>Japan Agency for Medical Research and Development (AMED)</funding><pagination>3261</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10241881</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Primary sclerosing cholangitis (PSC) is characterized by progressive biliary inflammation and fibrosis. Although gut commensals are associated with PSC, their causative roles and therapeutic strategies remain elusive. Here we detect abundant Klebsiella pneumoniae (Kp) and Enterococcus gallinarum in fecal samples from 45 PSC patients, regardless of intestinal complications. Carriers of both pathogens exhibit high disease activity and poor clinical outcomes. Colonization of PSC-derived Kp in specific pathogen-free (SPF) hepatobiliary injury-prone mice enhances hepatic Th17 cell responses and exacerbates liver injury through bacterial translocation to mesenteric lymph nodes. We developed a lytic phage cocktail that targets PSC-derived Kp with a sustained suppressive effect in vitro. Oral admi</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis.</pubmed_title><pmcid>PMC10241881</pmcid><funding_grant_id>JP21ek0109416</funding_grant_id><pubmed_authors>Golembo M</pubmed_authors><pubmed_authors>Jablonska J</pubmed_authors><pubmed_authors>Suzuki T</pubmed_authors><pubmed_authors>Sugimoto S</pubmed_authors><pubmed_authors>Sberro-Livnat H</pubmed_authors><pubmed_authors>Teratani T</pubmed_authors><pubmed_authors>Tabuchi T</pubmed_authors><pubmed_authors>Navok S</pubmed_authors><pubmed_authors>Konda M</pubmed_authors><pubmed_authors>Nakamoto N</pubmed_authors><pubmed_authors>Hayashi N</pubmed_authors><pubmed_authors>Chu PS</pubmed_authors><pubmed_authors>Bassan M</pubmed_authors><pubmed_authors>Khabra E</pubmed_authors><pubmed_authors>Zak N</pubmed_authors><pubmed_authors>Kowalsman N</pubmed_authors><pubmed_authors>Morikawa R</pubmed_authors><pubmed_authors>Buchshtab N</pubmed_authors><pubmed_authors>Taniki N</pubmed_authors><pubmed_authors>Kredo-Russo S</pubmed_authors><pubmed_authors>Shiota A</pubmed_authors><pubmed_authors>Kanai T</pubmed_authors><pubmed_authors>Fujimori S</pubmed_authors><pubmed_authors>Ben-Ishai N</pubmed_authors><pubmed_authors>Weinstock E</pubmed_authors><pubmed_authors>Miyamoto K</pubmed_authors><pubmed_authors>Mikami Y</pubmed_authors><pubmed_authors>Kasuga R</pubmed_authors><pubmed_authors>Weiner IN</pubmed_authors><pubmed_authors>Inbar D</pubmed_authors><pubmed_authors>Ichikawa M</pubmed_authors><pubmed_authors>Nicenboim J</pubmed_authors><pubmed_authors>Mordoch R</pubmed_authors><pubmed_authors>Aoto Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis.</name><description>Primary sclerosing cholangitis (PSC) is characterized by progressive biliary inflammation and fibrosis. Although gut commensals are associated with PSC, their causative roles and therapeutic strategies remain elusive. Here we detect abundant Klebsiella pneumoniae (Kp) and Enterococcus gallinarum in fecal samples from 45 PSC patients, regardless of intestinal complications. Carriers of both pathogens exhibit high disease activity and poor clinical outcomes. Colonization of PSC-derived Kp in specific pathogen-free (SPF) hepatobiliary injury-prone mice enhances hepatic Th17 cell responses and exacerbates liver injury through bacterial translocation to mesenteric lymph nodes. We developed a lytic phage cocktail that targets PSC-derived Kp with a sustained suppressive effect in vitro. Oral admi</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jun</publication><modification>2025-04-04T14:39:38.88Z</modification><creation>2025-04-04T14:39:38.88Z</creation></dates><accession>S-EPMC10241881</accession><cross_references><pubmed>37277351</pubmed><doi>10.1038/s41467-023-39029-9</doi></cross_references></HashMap>